In 1989, Professor Hortons team identified hepatitis C virus (HCV). The discovery of HCV was the first breakthrough in the history of hepatitis C research. Soon after, a detection method for HCV was established, which avoided the large-scale transmission of hepatitis C disease. In the early 1990s, HCV was basically eliminated from the blood bank, which effectively prevented the transmission of hepatitis C through blood transfusion.
Hepatitis C vaccine has experienced more than 30 years of research, but it has not been successfully developed. Together with AIDS vaccine and influenza virus vaccine, hepatitis C vaccine has been listed as a typical failure in vaccine development.
A researcher who has been studying hepatitis C virus in Shanghai Pasteur Institute of Chinese Academy of Sciences for a long time told the first finance and economics reporter: the research and development of hepatitis C virus vaccine has not yet been successful. Our hepatitis C vaccine has also been developed for several years, and has made some good progress. However, the attention of all circles on hepatitis C vaccine is still insufficient.
He explained to the first finance and economics reporter that the difficulty in developing hepatitis C vaccine lies in technology, because it is useful for genotypes 1, 2, 3, 4, 5, 6 and 7; on the other hand, it lies in the governments investment, because hepatitis C can be cured by drugs, which makes the research and development of the vaccine insufficient.
According to who statistics, as of 2018, the global HCV infection rate was about 3%, about 180 million people were infected with HCV, and about 40 million people were infected in China.
Before Mondays trading, shares of Gilead science, the largest producer of hepatitis C drugs, surged more than 3%.
In 2014, Gilead science caused a sensation in the field of hepatitis C treatment with sovaldi and harvoni, and ranked among the top 10 global pharmaceutical giants in terms of revenue. Gileads hepatitis C prescription drug became a blockbuster, winning the first sales of prescription drugs in that year with sales of 18 billion US dollars. In 2016, Gilead once again occupied the absolute dominant position in the hepatitis C market by virtue of eplusa. In 2017, the US FDA announced the approval of Gileads vosevi (Jisi generation). This drug is based on Gileads sofosbuvirs HCV directly acting on the anti viral (DAA) drug pipeline. It is also the ultimate weapon to eliminate hepatitis C virus.
In recent years, the cost of hepatitis C treatment in China has also decreased. Professor Yan Xuebing, director of infectious diseases department of Affiliated Hospital of Xuzhou Medical University, told the first finance and economics reporter: now the cost of hepatitis C treatment has been greatly reduced, and the treatment cost of Jisan generation is about 14000 yuan; Jisi generation has not entered the medical insurance, and the treatment cost for a course of treatment is nearly 100000 yuan. he said that the earliest price of sofosbuvir was as high as 1000 US dollars It should be continued for 84 days.
The researchers of Pasteur Institute in Shanghai told reporters from China first finance and Economics: drug treatment alone is not enough to fight against hepatitis C virus, and prevention is still needed. It is hoped that the discovery of hepatitis C virus will promote the development of hepatitis C vaccine
Professor Zhang Wenhong, director of the infection department of Huashan Hospital, also commented: in fact, important discoveries about pathogens in history have won Nobel Prize, including the discovery of hepatitis B virus and HIV. The award of the Nobel Prize once again proves that the field of infection is closely related to human evolution and human history, and has a profound impact.